Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016

Date: October 12, 2016
Pages: 577
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C02F9ED0611EN
Leaflet:

Download PDF Leaflet

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) Overview
Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance
Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies
Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
Drug Profiles
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
Appendix 554

LIST OF TABLES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Abeona Therapeutics, Inc. , H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alteogen Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corporation, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Elsalys Biotech SAS, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by enGene, Inc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by InMed Pharmaceuticals Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Innate Pharma S.A., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Merck & Co., Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Plc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Odan Laboratories Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pila Pharma AB, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Polyphor Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ProMetic Life Sciences Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteostasis Therapeutics, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Recipharm AB, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respira Therapeutics Inc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by rEVO Biologics, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SATT North SAS, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Selvita S.A., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synovo GmbH, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by TGV-Laboratories, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Therabron Therapeutics, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance Biopharma, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by U.S. Stem Cell, Inc., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unizyme Laboratories A/S, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vectura Group Plc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..1), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..2), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..3), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..4), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..5), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..6), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..7), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..8), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..9), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..10), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..11), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..12), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..13), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..14), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..15), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..16), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..17), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..18), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..19), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..20), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..21), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..22), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..23), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..1), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..2), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..3), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..4), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..5), H2 2016
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..6), H2 2016 557

LIST OF FIGURES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: